Immuneering Corp Files 8-K/A Amendment
Ticker: IMRX · Form: 8-K/A · Filed: Oct 2, 2024 · CIK: 1790340
| Field | Detail |
|---|---|
| Company | Immuneering Corp (IMRX) |
| Form Type | 8-K/A |
| Filed Date | Oct 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, director-change, executive-compensation
Related Tickers: IMRX
TL;DR
IMRX filed an 8-K/A, amending director and exec comp details from March. Watch for new board members and pay changes.
AI Summary
Immuneering Corporation filed an 8-K/A on October 2, 2024, amending a previous filing from March 11, 2024. The amendment pertains to the departure of a director, election of a new director, and changes in compensatory arrangements for certain officers. The filing does not specify the names of the individuals involved or the exact nature of the compensatory changes.
Why It Matters
This amendment to a previous filing indicates changes in the company's board of directors and executive compensation structure, which could signal shifts in corporate governance or strategic direction.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and does not disclose new material adverse events, indicating a low immediate risk.
Key Players & Entities
- Immuneering Corporation (company) — Registrant
- March 11, 2024 (date) — Date of earliest event reported
- October 2, 2024 (date) — Date of report
FAQ
What specific changes are being made to the board of directors?
The 8-K/A filing indicates the departure of a director and the election of a new director, but does not name the individuals involved.
What are the details of the changes in compensatory arrangements for certain officers?
The filing states that there are changes to compensatory arrangements for certain officers, but the specific details of these changes are not provided in the excerpt.
What was the original filing date that this 8-K/A amends?
This 8-K/A amends a filing originally dated March 11, 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 245 Main St. Second Floor, Cambridge, MA 02142.
What is Immuneering Corporation's IRS Employer Identification Number?
Immuneering Corporation's IRS Employer Identification Number is 26-1976972.
Filing Stats: 494 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-10-02 16:11:03
Key Financial Figures
- $0.001 — stered Class A common stock, par value $0.001 per share IMRX The Nasdaq Global Market
Filing Documents
- imrx-20240311.htm (8-K/A) — 21KB
- 0001790340-24-000073.txt ( ) — 149KB
- imrx-20240311.xsd (EX-101.SCH) — 2KB
- imrx-20240311_lab.xml (EX-101.LAB) — 23KB
- imrx-20240311_pre.xml (EX-101.PRE) — 13KB
- imrx-20240311_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNEERING CORPORATION Date: October 2, 2024 By: /s/ Michael D. Bookman Name: Michael D. Bookman Title: Chief Legal Officer and Secretary